Male hormonal contraceptives

REFERENCES

• WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia by testosterone enanthate in normal men. Lancet (1990) 336:995–999.
   Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil. Steril. (1996) 65:821-829. **Landmark study that demonstrated thatexogenous high-dose T provides efficacious
   Google Scholar
• YOUNG NR, BAKER HG, LIU G, SEEMAN E: Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception. Clin. Ender:dna Metab. (1993) 77:1028–1032.
   PubMed Web of Science ®Google Scholar
• ANDERSON R, WU FC: Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. Clin. Ender:dna Metab. (1996) 81:896–901.
   Google Scholar
• BEHRE HM, ABSHAGEN K, OETTELM, HUBLER D, NIESCHLAG E: Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur. Endecrina (1999) 140:414–419.
   PubMed Web of Science ®Google Scholar
• ZHANG G, GUY, WANG X, CUI Y, BREMNER WJ: A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. j Andrei (1998) 19:761–768.
   PubMedGoogle Scholar
• ZHANG G, GUY, WANG X, CUI Y, BREMNER WJ: A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. Clin. EndecfineL Metab. (1999) 84:3642–3647.
   PubMed Web of Science ®Google Scholar
• KAMISCHKE A, PLO GER D, VENHERM S et al.: Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin. EndecnPul. (2000) 53:43–52.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, NIESCHLAG E: Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting ester. j Chu. Endocrirrol Metab. (1992) 75:1204–1210.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, BAUS S, KLIESCH S: Potential of testosterone buciclate for male contraception: endocrine differences between responders and non-responders. Chu. Endocnnol Metab. (1995) 80:2394–2403.
   PubMed Web of Science ®Google Scholar
• BHASIN S, SWERDLOFF RS, STEINER B: A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. j Chu. Endocrirrol. Metab. (1992) 74:75–83.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, BOYLAN L: Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Chi] Endocrirrol Metab. (1990) 71:216–222.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, BOYLAN L: Suppression of human spermatogenesis by testosterone implants. Chu. Endocnnol Metab. (1992) 75:1326–1332.
   PubMed Web of Science ®Google Scholar
• MCLACHLAN RI, MCDONALD J, RUSHFORD D et al: Efficacy and acceptability of testosterone implants, alone or in combination with a 5-a reductase inhibitor, for male hormonal contraception. Contraception (2000) 62:73–78.
   PubMed Web of Science ®Google Scholar
• COERT A, GEELEN J, DE VISSER J, VAN DER VIES J: The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active. Acta Endocrirrol. (Coperrh) (1975) 79:789–800.
   PubMedGoogle Scholar
• MERIGGIOLA M, BREMNER WJ, CONSTANTINO A et al: An oral regimen of cyproterone acetate and testerone for spermatogenic suppression in men. Feral Stern. (1997) 68:844–850.
   PubMed Web of Science ®Google Scholar
• AMORY JK, MATSUMOTO AM: The therapeutic potential of testosterone patches. Exp. Opin. Invest. Drugs (1998) 7:1977–1985.
   PubMedGoogle Scholar
• BUCHTER D, VON ECKARDSTEIN S, VON ECKARDSTEIN A et al: Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. Chu. Endocnnol Metab. (1999) 84:1244–1249.
   PubMed Web of Science ®Google Scholar
• THE MEDICAL LETTER: Androgel. TheMedical Letter on Drugs and Therapeutics. (2000) 42:49–51.
   PubMed Web of Science ®Google Scholar
• CUMMINGS D, KUMAR N, BARDIN CW, SUNDARAM K, BREMNER WJ: Prostate-sparing effects in primates of the potent androgen 7a-methy1-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. j Chu. Endocrirrol Metab. (1998) 83:4212–4219.
   PubMed Web of Science ®Google Scholar
• SUVISSARI J, SUNDARAM K, NOE Getal.: Pharmacokinetics and pharmacodynamics of 7a-methy1-19-nortestosterone and intramuscular administration in healthy men. Hum. Reprod. (1997) 12:967–973.
   Google Scholar
• SUNDARAM K, KUMAR N: la-methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapy. Int. I Andra. (2000) 23:13–15.
   PubMedGoogle Scholar
• NOE G, SUVISSARI J, MARTIN C etal.: Gonadotrophin and testosterone suppression by 7a-methy1-19-nortestosterone acetate administered by subdermal implant to healthy men. Hum. Reprod. (1999) 14:2200-2206. •MENT acetate rods suppress circulating gonadotropin levels 95% below baseline for a full month after implantation.
   Google Scholar
• HAMANN LG, HIGUCHI RI, ZHI L et al.: Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono [5,6-gl quinolines. j Med. Chem. (1998) 41:623–639.
   PubMed Web of Science ®Google Scholar
• HAMANN LG, MANI NS, DAVIS RL et al.: Discovery of a potent orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1, 2,3, 4 -tetrahydro- 6-(trifluoromethyl) -8-pyridono15,6g1-quinoline (LG121071). j Med. Chem. (1999) 42:210–212.
   PubMed Web of Science ®Google Scholar
• NEGRO-VILAR A: Selective androgen receptor modulators: a novel approach to androgen therapy for the new millennium. Chu. Endocrirrol Metab. (1999) 84:3459–3462.
   PubMed Web of Science ®Google Scholar
• PAVLOU SN, BREWER K, FARLEY MG et al: Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. j Chu. Endocnnol. Metab. (1991) 73:1360–1369.
   PubMed Web of Science ®Google Scholar
• TOM L, BHASIN S, SALAMEH W et al:Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. j Chu. Endocrirrol Metab. (1992) 75:476–483.
   PubMed Web of Science ®Google Scholar
• BAGATELL CJ, MATSUMOTO AM, CHRISTENSEN RB, RIVIER JE, BREMNER WJ: Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. Chu. Endocrirrol Metab. (1993) 77:427–432.
   PubMed Web of Science ®Google Scholar
• SWERDLOFF RS, BAGATELL CJ, WANG C et al: Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. I Chu. Endocnnol Metab. (1998) 83:3527–3533.
   PubMed Web of Science ®Google Scholar
• HERBST KL, ANAWALT BD, AMORY JK, NOSBISCH C, BREMNER WJ: Acyline: a potent new gonadotropin-releasing hormone (GnRH) antagonist without side effects. Endocrine Societyjs 83rd Annual Meeting (2001):130.
   Google Scholar
• CHO N, HARADA M, IMAEDA T et al:Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. j Med. Chem. (1998) 41:4190–4195.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA M, BEBB RA, ANAWALT BD et al.: Progesterone-testosterone trials for male contraception. In: Male Contraception: Present and Future. Rajalakshmi M & Griffin PD (Eds.), New Age International (P) LTD, New Delhi, India (1997):219–234.
   Google Scholar
• BEBB RA, ANAWALT BD, CHRISTENSEN RB et al: Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. j Chu. Endocnnol Metab. (1996) 81:757–762.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, HOWE C, TURNER L, MACKEY MA: Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. j Chu. Endocrirrol Metab. (1996) 81:4113–4121.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA M, BREMNER WJ, PAULSEN CA et al.: A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. j Chu. Endocrirrol Metab. (1996) 81:3018-3023. ••T+ CPA is highly effective in inducingazoospermia and causes few adverse effects.
   Google Scholar
• ANAWALT BD, BEBB RA, BREMNER WJ, MATSUMOTO AM: A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. j. Androl. (1999) 20:407–414.
   PubMed Web of Science ®Google Scholar
• WU FC, BALASUBRAMANIAN R, MULDERS TM, COELINGH-BENNICK HJ: Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. j. Clin. Endocrinol. Metab. (1999) 84:112–122.
   PubMed Web of Science ®Google Scholar
• ANAWALT BD, HERBST KL, MATSUMOTO AM et al.: Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Feral. Steril. (2000) 74:707–714.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA M, BREMNER WJ, CONSTANTINO A, DICINTIO B, FLAGMINI C: Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum. Reprod. (1998) 13:1225–1229.
   PubMed Web of Science ®Google Scholar
• KAMISCHKE A, DIEBACKER J, NIESCHLAG E: Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function. Clin. Endocrinol. (2000) 53:351–358.
   PubMed Web of Science ®Google Scholar
• KAMISCHKE A, VENHERM S, PLOGER D, VON ECKARDSTEIN S, NIESCHLAG E: Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. j. Clin. Endocrinol. Metall. (2001) 86:303–309.
   PubMed Web of Science ®Google Scholar
• MARTIN C, ANDERSON R, CHENG L etal.: Potential impact of hormonal male contraception: cross cultural implications for development of novel preparations. Hum. Reprod. (2000) 15:637–645.
   Google Scholar
• CORTES M, FLICK A, BARONE Metal.:Results of a pilot study of the time to azoospermia after vasectomy in Mexico City. Contraception (1997) 56:215–222.
   Google Scholar
• ANDERSON R, WALLACE A, WU FC: Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5a-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. Endocrinol. Metall. (1996) 81:902–908.
   Google Scholar
• KINNIBURGH D, ANDERSON R, BAIRD D: Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by the addition of finasteride. Androl. (2001) 22:88–95.
   Web of Science ®Google Scholar
• WEINBAUER G, SCHLATT S, WALTER V, NIESCHLAG E: Testosterone-induced inhibition of spermatogenesis is more closely related to suppression of FSH than to testicular androgen levels in the cynomolgus monkey model (maraca fascicularis). j Endocrinol. (2001) 168:25–38.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, FARLEY TM, PERGOUDOV A, WAITES GM: WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. Ferri/. Sterif (1995) 63:125–133.
   PubMed Web of Science ®Google Scholar